News
CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...
Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.
Zacks Investment Research on MSN4d
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 injectable therapies, Zepbound and Wegovy, leading the field. Although Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback